Does Regence Cover Forteo (Teriparatide)? Coverage Rules, Prior Auth, and Cost Options Explained

What Is Forteo and Why Does Coverage Complexity Matter?

Forteo is the brand name for teriparatide, a recombinant form of the 1-34 amino-acid fragment of human parathyroid hormone. The FDA approved teriparatide in 2002 for postmenopausal women and men with osteoporosis at high fracture risk, and again for glucocorticoid-induced osteoporosis in both sexes [1]. Unlike antiresorptive drugs such as alendronate or denosumab, teriparatide is anabolic: it stimulates new bone formation rather than simply slowing bone loss.

Because the drug is a self-administered daily injection dispensed through specialty pharmacy channels, its list price runs roughly $3,000 to $4,500 per month. That price point places it firmly in the specialty tier of every major insurer, including Regence BlueCross BlueShield plans operating across Alaska, Idaho, Oregon, Utah, and Washington.

The Clinical Basis for Coverage Restrictions

The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend anabolic therapy such as teriparatide as a first-line or second-line option specifically for patients at "very high" fracture risk, defined as a prior hip or vertebral fracture, a T-score at or below -3.0, or continued fractures on antiresorptive therapy [2]. Regence coverage criteria closely follow these definitions.

FDA-Label Duration Limit

The FDA label for Forteo specifies a maximum cumulative lifetime use of 24 months. This is not an arbitrary payer restriction, it reflects the original clinical trial design. Regence PA approvals are typically issued in 6-month increments with reassessment, up to that 24-month ceiling.

How Regence Formularies Classify Forteo

Regence operates multiple plan types: individual and family (ACA marketplace), employer-sponsored fully insured, self-funded employer plans, Medicare Advantage, and Medicaid managed care partnerships. Formulary placement can differ across these plan types.

Commercial and Employer Plans

On most Regence commercial formularies, Forteo sits on Tier 4 or Tier 5 (specialty). Tier 4 copays for specialty drugs in typical Regence benefit designs run from $100 to $300 per 28-day supply after meeting the deductible; Tier 5 drugs may require a coinsurance of 25-33% with no cap unless the plan has an out-of-pocket maximum that kicks in. Members should pull the specific Summary of Benefits and Coverage (SBC) document for their plan year, because tier placement is not uniform.

Medicare Advantage Plans

Regence Medicare Advantage plans (such as Regence MedAdvantage+) place teriparatide on Part D specialty tier. Under standard Part D cost-sharing in 2025, the catastrophic coverage phase begins once a member's true out-of-pocket spending reaches $2,000 (per the Inflation Reduction Act cap effective 2025), after which cost-sharing drops to zero for the remainder of the year [3]. This change significantly improves affordability for Medicare beneficiaries who previously faced 25-33% coinsurance in the coverage gap.

Biosimilar Bonsity as a Tier Alternative

Bonsity (teriparatide injection 620 mcg/2.4 mL), approved by the FDA in June 2021 as the first teriparatide biosimilar, may occupy a lower formulary tier on some Regence plans [4]. If Forteo brand is on Tier 5 and Bonsity is on Tier 4, the monthly cost difference to the patient could exceed $150. Physicians can write "biosimilar permitted" on the prescription or, if clinically appropriate, write specifically for Bonsity.

Prior Authorization Criteria for Forteo on Regence Plans

Prior authorization (PA) is required. The exact criteria depend on the specific plan document, but Regence PA criteria for teriparatide across commercial plans typically include all of the following:

Diagnosis Requirements

• Documented postmenopausal osteoporosis, male osteoporosis, or glucocorticoid-induced osteoporosis (the three FDA-approved indications [1])
• DXA scan confirming a T-score <-2.5 at the lumbar spine, total hip, or femoral neck, OR a T-score <-2.5 with a prior low-trauma fracture

The National Osteoporosis Foundation (now Bone Health and Osteoporosis Foundation, BHOF) recommends pharmacologic treatment for postmenopausal women and men age 50 and older who have a hip or vertebral fracture, or a T-score <-2.5, or a 10-year hip fracture probability at or above 3% by FRAX [5]. Regence medical policies align with these thresholds in most plan documents.

Step Therapy (Fail-First) Requirement

Most Regence PA forms require documented trial and failure of, or medical contraindication to, at least one bisphosphonate (alendronate 70 mg weekly, risedronate 35 mg weekly, or zoledronic acid 5 mg IV annually are the most commonly specified agents). Denosumab 60 mg every 6 months is sometimes accepted as an equivalent prior-line agent.

Failure is defined in most Regence criteria as one of the following:

1. New fracture after at least 12 months of compliant bisphosphonate therapy
2. Continued decline in BMD (T-score worsening by 0.03 g/cm² or more at two consecutive DXA scans) despite compliant therapy
3. Documented intolerance, upper GI toxicity, osteonecrosis of the jaw, atypical femoral fractures, or inability to comply with dosing instructions (e.g., esophageal stricture precluding oral bisphosphonate use)

Clinical Documentation the PA Package Must Include

• Most recent DXA report (within 24 months)
• FRAX score printout if borderline T-score
• Documentation of prior bisphosphonate trial or contraindication letter
• Prescriber attestation of "high" or "very high" fracture risk
• If glucocorticoid-induced: current corticosteroid dose and duration (prednisone equivalent ≥5 mg/day for ≥3 months, per American College of Rheumatology 2022 guideline criteria [6])

Clinical Evidence Supporting Teriparatide Coverage

Payers base medical necessity criteria partly on trial data. The evidence base for teriparatide is substantial.

The FPT Trial

The Fracture Prevention Trial (FPT, N=1,637) randomized postmenopausal women with prior vertebral fractures to teriparatide 20 mcg/day, 40 mcg/day, or placebo for a median of 21 months. Teriparatide 20 mcg reduced the relative risk of new vertebral fractures by 65% (RR 0.35, 95% CI 0.22 to 0.55, P<0.001) and reduced non-vertebral fragility fractures by 53% (RR 0.47, 95% CI 0.25 to 0.88) compared with placebo [7]. This trial is the primary basis for the FDA indication and for insurer medical necessity definitions.

Glucocorticoid-Induced Osteoporosis Evidence

A randomized trial by Saag et al. (N=428) compared teriparatide 20 mcg/day with alendronate 10 mg/day over 36 months in patients on long-term glucocorticoid therapy. Teriparatide increased lumbar spine BMD by 7.2% versus 3.4% for alendronate (P<0.001), and reduced vertebral fracture incidence by 90% relative to alendronate [8]. This head-to-head finding supports the step-up to anabolic therapy in patients already on bisphosphonates who fracture or continue to lose bone.

Sequential Therapy Considerations

The AACE 2020 clinical practice guidelines state: "Patients at very high fracture risk should receive anabolic therapy first, followed by antiresorptive therapy to maintain gains." [2] Following teriparatide, a transition to an antiresorptive agent (typically denosumab or a bisphosphonate) is standard of care to preserve the BMD gains achieved. Regence PA renewal criteria sometimes ask for a transition plan at month 18 to month 24.

Step-by-Step: How to Submit a Regence Prior Authorization for Forteo

Getting the PA right the first time reduces denial rates. Here is a practical sequence for prescribers and office staff.

Step 1. Verify the Patient's Specific Plan

Call Regence provider services (the number on the member's card) or use the Regence provider portal to confirm the plan name, formulary year, and whether teriparatide requires PA under medical or pharmacy benefit. Some Regence plans cover injectables under the medical benefit (J-code J3110 for teriparatide), which changes the cost-sharing structure entirely.

Step 2. Obtain the Correct PA Form

Download the current Specialty Drug Prior Authorization Request Form from the Regence provider portal. Forms are updated each January 1. Using a prior year's form is a common reason for administrative denial.

Step 3. Assemble the Clinical Package

Attach the DXA report, FRAX calculation, office notes documenting prior therapy and outcomes, and any adverse event documentation. If a bisphosphonate was contraindicated rather than failed, attach a signed letter of medical necessity explaining the contraindication with reference to the relevant clinical literature, for example, citing the FDA label warning on bisphosphonates for patients with creatinine clearance <35 mL/min [9].

Step 4. Submit and Track

Regence is required by state insurance law in Oregon, Washington, Idaho, and Alaska to respond to standard PA requests within 3 business days and urgent requests within 24 hours. Confirm the turnaround commitment with the plan at submission.

Step 5. If Denied, Request a Peer-to-Peer Review Immediately

Before filing a formal appeal, most Regence plans allow the prescribing physician to speak directly with the plan's medical director or reviewing physician. This conversation often resolves denials that stem from incomplete documentation rather than a coverage policy disagreement. Request the peer-to-peer within 72 hours of the denial notice.

What to Do If Regence Denies Coverage for Forteo

A denial is not the end of the road.

First-Level Internal Appeal

File a written first-level appeal within 180 days of the denial (or the timeframe stated in the Explanation of Benefits). Attach a detailed letter of medical necessity citing the FPT trial data [7], the AACE guidelines [2], and the patient's specific clinical history. Studies of specialty drug appeals across commercial payers suggest that 30 to 50% of first-level appeals succeed when supported by clinical documentation.

External Independent Review

If Regence upholds the denial at the first-level appeal, members in Oregon, Washington, Idaho, and Alaska have a right to request an external independent review through the state's insurance commissioner. External reviewers are not employed by the insurer and overturn plan decisions in a meaningful share of cases involving specialty medications.

Step Down to Bonsity or Request Exception

If brand Forteo is denied but biosimilar Bonsity is on formulary, a formulary exception may not be necessary, the prescriber can simply write for Bonsity. Alternatively, request a formulary exception for Forteo brand if there is a specific clinical reason to prefer it (e.g., patient already stable on Forteo pen device and unable to use the Bonsity multi-dose vial).

Out-of-Pocket Cost Reduction Options

Even with coverage, specialty tier cost-sharing can be significant.

Eli Lilly Forteo Savings Card (Commercial Plans Only)

Eli Lilly offers a copay savings program for commercially insured patients. As of 2025, eligible patients with commercial insurance may pay as little as $5 per month, with Lilly covering up to $350 per prescription fill. The program excludes patients on federal or state government insurance programs (Medicare, Medicaid, TRICARE). Enrollment is at LillyMedicare.com or through the prescriber's office.

Patient Assistance Program

Lilly Cares Foundation provides Forteo at no cost to uninsured or underinsured patients who meet income criteria (typically at or below 400% of the federal poverty level). Applications are submitted through the Lilly Cares website or by calling 1-800-545-5979.

340B Program Eligibility

Patients receiving care at a qualifying federally qualified health center (FQHC) or other 340B-covered entity may access teriparatide at substantially reduced acquisition cost, which the provider can then pass through to the patient. Not all prescribers participate; ask the dispensing pharmacy whether the prescribing entity is 340B-enrolled.

Specialty Pharmacy Negotiated Rates

Regence typically channels specialty drugs through a preferred specialty pharmacy network (often Walgreens Specialty or Briova/OptumRx depending on the plan year). Using an out-of-network specialty pharmacy for a specialty-tier drug can increase cost-sharing significantly. Confirm the preferred specialty pharmacy before the first fill.

Glucocorticoid-Induced Osteoporosis: A Special Coverage Consideration

Patients on chronic glucocorticoid therapy represent a distinct clinical group with accelerated bone loss and fracture risk disproportionate to T-score alone. The American College of Rheumatology 2022 guideline on glucocorticoid-induced osteoporosis conditionally recommends teriparatide over oral bisphosphonates for high-risk patients on prednisone ≥7.5 mg/day for ≥6 months with a prior fracture or T-score <-2.5 [6].

Regence PA criteria for glucocorticoid-induced osteoporosis differ slightly from the standard postmenopausal criteria. Step therapy with a bisphosphonate may be waived if the patient is already on a moderate-to-high glucocorticoid dose and meets fracture-risk thresholds, because the Saag et al. Trial [8] demonstrated superiority of teriparatide over alendronate in this population specifically.

Prescribers should document the specific corticosteroid, the dose in prednisone equivalents, and the duration of use in the PA package for glucocorticoid-induced osteoporosis patients.

Monitoring Requirements That Support Continued Coverage

Regence PA renewals (every 6 months up to 24 months) typically require updated clinical documentation. Meeting these requirements proactively prevents mid-treatment coverage gaps.

Required at Each Renewal

• Office visit note documenting ongoing high fracture risk
• Absence of new adverse events (hypercalcemia, osteosarcoma risk discussion, injection-site reactions)
• For glucocorticoid-induced osteoporosis: confirmation that glucocorticoid therapy is still ongoing

DXA Monitoring Frequency

The BHOF recommends repeat DXA every 1 to 2 years during anabolic therapy to track response [5]. Regence does not typically require a repeat DXA for each 6-month PA renewal, but will ask for one at 12 to 18 months to confirm treatment response before approving the final phase of the 24-month course.

Serum calcium should be checked 16 hours after the first injection and periodically thereafter, as teriparatide can cause transient hypercalcemia, particularly in patients with primary hyperparathyroidism or Paget's disease, both of which are contraindications to use [1].

Transition Planning After 24 Months

Because the FDA label limits teriparatide to 24 months lifetime use, both the treating physician and Regence expect a documented plan for sequential antiresorptive therapy before the final renewal is approved.

Without a subsequent antiresorptive, BMD gains from teriparatide are largely lost within 12 to 18 months after stopping. The DATA-Switch trial (N=94) demonstrated that transitioning to denosumab after teriparatide produced continued BMD gains at the lumbar spine of 6.6% over 24 months post-switch, significantly better than the reverse sequence [10]. Denosumab 60 mg every 6 months or zoledronic acid 5 mg IV annually are the most common post-teriparatide choices, and both require their own PA processes with Regence.